PubMed Health⌕ Search

Biomedical subjects

S Dekio

Publications and source records attributed to S Dekio.

At least 37 records · Page 2Linked to original sources
PubMed1995

In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

OBJECTIVE: To examine in vitro antimycobacterial activity of levofloxacin. DESIGN: Minimum inhibitary concentrations (MICs) of levofloxacin for various mycobacterial species were determined by the agar dilution method using 7H11 medium and compared with those of ofloxacin. Antimicrobial activity of levofloxacin against Mycobacterium tuberculosis and M. intracellulare phagocytosed in murine peritoneal macrophages was measured in terms of reducing cell-associated bacterial colony forming units (CFUs). RESULTS: MICs of levofloxacin against M. tuberculosis, M. kansasii, M. marinum, M. scrofulaceum, M. avium, M. intracellulare, M. fortuitum, and M. chelonae were 2 to 4 times lower than those of ofloxacin. Levofloxacin exhibited higher efficacy in reducing bacterial CFUs in macrophages than ofloxacin. CONCLUSION: Levofloxacin possessed more potent in vitro antimycobacterial activities as compared to that of ofloxacin.

Animals↗
PubMed1995

Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.

A new benzoxazinorifamycin, KRM-1648 (KRM), was studied for its therapeutic efficacy in combination with other antimicrobials against Mycobacterium avium complex infections in mice. When M. intracellulare-infected (intravenously) mice were given KRM, clarithromycin (CAM), sparfloxacin (SPFX), or ethambutol (EB) each alone or in combination, by gavage, once daily 6 times per week (streptomycin [SM] was given subcutaneously twice per week) from day 1, KRM + CAM exhibited combined efficacy in terms of reducing the incidence of gross lung lesions and the bacterial loads in the lungs and spleens. The addition of either EB or EB + SPFX to KRM + CAM increased the efficacy. Moreover, the multi-drug regimen of KRM + CAM + EB + SPFX or ofloxacin [OFLX]) was more efficacious than rifampicin (RMP) + CAM + EB + SPFX (or OFLX). In M. avium infection, KRM + clofazimine was the most efficacious among two-drug combinations tested followed by KRM + SM. KRM + CAM was considerably less effective against M. avium than against M. intracellulare infection. KRM + EB and KRM+OFLX failed to show such a combined effect.

Animals↗
PubMed1994

Hair fibrous protein compositions in some hereditary hair abnormalities determined by two-dimensional polyacrylamide gel electrophoresis.

S-carboxymethylated (SCM) fibrous proteins (FPs) from the scalp hairs of the three different hereditary hair abnormalities (trichorrhexis invaginata in Netherton's syndrome, pili trianguli et canaliculi in uncombable hair syndrome, and fine hair in anhidrotic ectodermal dysplasia) were analyzed by two-dimensional polyacrylamide gel electrophoresis. Comparison of the SCM FP compositions of the three hair abnormalities with that of the normal revealed that the SCM FP compositions of these three abnormal hairs were all electrophoretically different from each other and that of the normal.

Child↗
PubMed1994

Tinea corporis due to Trichophyton verrucosum: report of a patient from the San'in District.

A 70-year-old Japanese housewife, a resident of Shimane Prefecture, developed an erythematous, annular skin lesion on her right forearm. Mycological examinations revealed that it was tinea corporis caused by Trichophyton verrucosum (T. verrucosum). This fungus was then shown to have been transmitted to her from young dairy cattle introduced from the Hokkaido District to the ranch of her son. To the best of our knowledge, she is the first reported patient with tinea due to T. verrucosum who was infected in the San'in District.

Aged↗
PubMed1994

Mycobacterium malmoense isolated from soil.

Mycobacterium malmoense was isolated from a soil sample, and biological, biochemical, antigenic, and genetic characteristics of the isolate were described. This is the first report of isolation of this organism in Japan.

Mycobacterium↗
PubMed1994

In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.

A new fluoroquinolone, DU-6859a, was studied for its in vitro and in vivo antimycobacterial activities. MIC determination by the agar dilution method with 7H11 medium revealed that DU-6859a had MICs at which 90% of M. kansasii (0.78 microgram/ml), M. marinum (1.56 micrograms/ml), M. scrofulaceum (1.56 micrograms/ml), M. fortuitum (0.39 microgram/ml), M. chelonae subsp. abscessus (6.25 micrograms/ml), and M. chelonae subsp. chelonae (1.56 micrograms/ml) were inhibited were 4 to 32 times lower than those of ofloxacin and sparfloxacin. The MICs of DU-6859a at which 90% of M. tuberculosis (0.2 microgram/ml) and M. avium-M. intracellulare complex (12.5 micrograms/ml each) were inhibited were comparable to those of sparfloxacin but were four- to eightfold lower than those of ofloxacin. Thus, DU-6859a possessed more potent in vitro activity than sparfloxacin and ofloxacin against most mycobacterial species. DU-6859a exerted significant efficacy against infections caused by M. intracellulare and M. chelonae subsp. abscessus induced in mice when it was given at a dose of 1 mg per mouse (ca. 50 mg/kg of body weight) in terms of reducing the frequency of occurrence and the degree of gross pulmonary or renal lesions and bacterial loads in the lungs, spleens, or kidneys. The efficacy of DU-6859a was greater than that of ofloxacin and was more pronounced against M. chelonae infections than against M. intracellulare infections.

Animals↗
PubMed1994

Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.

In this study, the in vitro and in vivo anti-Mycobacterium leprae activity of the newly developed benzoxazinorifamycin, KRM-1648, in combination with clofazimine (CFZ) or dapsone (DDS) was evaluated. In vitro anti-M. leprae activities of KRM-1648, CFZ, and DDS along with their combinations were measured by the BACTEC 460 TB System. KRM-1648 (0.01 microgram/ml), CFZ (0.5 microgram/ml), and DDS (2.0 micrograms/ml exhibited a significant anti-M. leprae activity, reducing growth index (GI) values by 78%, 30%, and 35% by day 18, respectively. Combinations of KRM-1648 with either CFZ or DDS, or both caused only a slight increase in the efficacy. BALB/c nude mice infected subcutaneously with 1 x 10(6) of M. leprae Thai-53 strain and test drugs were given to mice by gavage once daily six times per week for up to 50 days, from day 31 to day 80. Animals were observed for the growth of organisms in the hindfoot pad during the 12 months following infection. KRM-1648 given at the dose of 0.001 mg/mouse exhibited potent antileprosy activity. KRM-1648 exhibited a significant combined effect with either CFZ or DDS, or both against M. leprae infection, except that there was no significant difference in efficacy between KRM-1648 + CFZ and CFZ alone. Furthermore, the efficacy was most increased in the three-drug regimen KRM-1648 + CFZ + DDS.

Animals↗
PubMed1993

[Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered in various frequencies per week in Mycobacterium intracellulare-infected mice].

Mice were infected intravenously with M. intracellulare (5.2 x 10(6) CFU/mouse) and then were given 0.4 mg of KRM-1648 emulsified in 2.5% gum arabic-0.2% Tween 80 by gavage, once daily 1, 3 or 6 times per week, from 24h after infection to the end of experiment (week 8). Evaluation of the therapeutic efficacy of the drug against the infection was done on the basis of incidence and degree of gross lung lesions, organ weight (square root of organ (mg)/body (g) x 10), and bacterial loads in the lungs and spleen. The lung lesions were not observed in all experimental groups at 4 weeks after infection. At 8 weeks after infection, the lung lesions observed in all control and solute (2.5% gum arabic-0.2% Tween 80) control mice, whereas 3 of the 5 mice given KRM-1648, 3 times per week and all of 5 mice given KRM-1648, 6 times per week showed no lung lesions. Although lung lesions were observed in all mice given KRM-1648 only once per week, the degree of the lesions was much more milder in KRM-1648-treated mice than in solute control mice. The spleen weight of solute control mice and KRM-treated mice differed from each other 4 and 8 weeks after infection, especially in mice administered 6 times per week. The CFUs of organisms in the lungs and spleen were lower in mice treated with the agent than in mice given solute at 4 and 8 weeks after infection, in orders of administration of 6, 3 and 1 times per week.

Animals↗
PubMed1992

Some biochemical characteristics of a partially purified extracellular keratinase from Trichophyton schoenleinii.

A Trichophyton schoenleinii (T. schoenleinii) strain from tinea favus was cultured in a liquid medium, from which an extracellular keratinase extract was obtained. The keratinase was partially purified with carboxymethyl-cellulose (CMC) column chromatography. Some biochemical characteristics of the keratinase were then examined. Its molecular weight was estimated to be 38,000 on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The optimal temperature was 50 degrees C, and the optimal pH value was 5.5. The keratinolytic activity was specifically increased by Fe++ and Fe .

Animals↗
PubMed1991

Lupus miliaris disseminatus faciei--report of a case in an elderly woman.

A 71-year-old Japanese woman developed red-brown to yellow papules symmetrically on the eyelids and cheeks. The histopathology of a papule showed caseation necrosis surrounded by epitheloid cells intermingled with giant cells in the dermis. The patient was thus diagnosed as lupus miliaris disseminatus faciei (LMDF). To the best of our knowledge, no LMDF patients of such an age have been described previously.

Aged↗